治疗慢性丙型肝炎新药Sofosbuvir  

A New Drug for Chronic Hepatitis:C-Sofosbuvir

作　　者：吴叶红[1] 刘海净[1] 刘欢[1] 

机构地区：[1]开滦总医院,河北唐山063000

出　　处：《中国药师》2014年第7期1224-1226,共3页China Pharmacist

摘　　要：鉴于丙型肝炎病毒(HCV)感染全球高发趋势,目前治疗方案因禁忌、严重不良反应等导致其使用的局限性,因此需要一种更有效、安全、简便、不适宜干扰素治疗的治疗药物。Sofosbuvir是具有这些特性的直接抗病毒药物,为HCV NS5 B聚合酶的尿苷核苷酸类似物抑制药,可有效对抗多种基因型HCV感染,具有良好的安全性和耐受性。本文综述Sofosbuvir的作用机制、药动学、不良反应、药物相互作用及临床试验。In view of the high incidence trend of chronic hepatitis C virus infection in globe and the limitations caused by contraindication and severe adverse reactions of the treatment regimens,one kind of medicine with higher efficacy,safety and convenience is in urgent need for the interferon-free treatment of patients with chronic hepatitis C virus infection.Sofosbuvir is a direct antiviral agent with the above advantages.It is a pyrimidine nucleotide analog inhibitor for hepatitis C virus （HCV） NS5B polymerase,and exhibits potent antiviral activity against several hepatitis C virus genotypes with promising safety and tolerance.The action mechanisms,pharmacokinetics,adverse reactions,drug interactions and clinical study of sofosbuvir were introduced in this paper.

关 键 词：Sofosbuvir 丙型肝炎病毒 药理学 药动学 临床试验 药品不良反应 

分 类 号：R978.7[医药卫生—药品]